Development
Predictmedix AI Inc.
PMED
CNSX
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -93.14% | -93.12% | -91.84% | -74.81% | -36.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -93.14% | -93.12% | -91.84% | -74.81% | -36.80% |
| Cost of Revenue | -100.00% | -100.00% | -100.00% | -83.58% | -70.14% |
| Gross Profit | -90.69% | -90.15% | -86.92% | -69.72% | 3.01% |
| SG&A Expenses | 53.43% | 49.00% | 20.53% | -1.28% | -26.03% |
| Depreciation & Amortization | -18.77% | 1.15% | 34.86% | 94.73% | 6,827.27% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.33% | 39.73% | 16.83% | 0.84% | -13.09% |
| Operating Income | -46.81% | -49.27% | -27.59% | -6.76% | 11.72% |
| Income Before Tax | -37.70% | -36.41% | -18.11% | -4.43% | 8.56% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.70% | -36.41% | -18.11% | -4.43% | 8.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.70% | -36.41% | -18.11% | -4.43% | 8.56% |
| EBIT | -46.81% | -49.27% | -27.59% | -6.76% | 11.72% |
| EBITDA | -51.12% | -52.92% | -29.66% | -4.10% | 15.50% |
| EPS Basic | -13.60% | -16.28% | -6.87% | 2.16% | 12.59% |
| Normalized Basic EPS | -14.10% | -17.50% | -8.64% | 2.30% | 12.36% |
| EPS Diluted | -13.60% | -16.28% | -6.87% | 2.16% | 12.59% |
| Normalized Diluted EPS | -14.10% | -17.50% | -8.64% | 2.30% | 12.36% |
| Average Basic Shares Outstanding | 22.47% | 17.43% | 10.34% | 5.79% | 4.61% |
| Average Diluted Shares Outstanding | 22.47% | 17.43% | 10.34% | 5.79% | 4.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |